Most clinicians meet histamine first in immunology, where mast cell histamine drives the allergic response. That is one piece of the story, and not the most clinically important piece for psychiatry. In the brain, histamine is a small but mighty system that promotes wakefulness.
Histamine neurons originate in the tuberomammillary nucleus of the hypothalamus and project broadly to cortex, thalamus, and brainstem. The pattern is by now familiar — a small source, broad projection, modulator function. When these neurons fire, the brain is awake. When they fall silent, the brain drifts toward sleep. Histamine works in concert with the orexin system to keep wakefulness stable across the day.
Antihistamines were introduced as allergy medications. The first generation — diphenhydramine, hydroxyzine, chlorpheniramine — were designed to block peripheral histamine receptors and quiet the runny nose. They worked, with one large incidental effect: they were small, lipophilic molecules that crossed the blood-brain barrier easily. They blocked central H1 receptors as readily as peripheral ones. The result was sedation, dry mouth, and — in older patients — a measurable cognitive hit.
Second-generation antihistamines — loratadine, cetirizine, fexofenadine — were engineered specifically to not cross the blood-brain barrier well. They block peripheral H1 receptors but leave central wakefulness signaling alone. The allergic patient gets relief without the cognitive penalty. Same target, two compartments, two clinical profiles.
This makes diphenhydramine an underappreciated problem in geriatric medicine. Sold over the counter as a sleep aid, marketed as harmless, it carries triple liabilities in older patients: H1 blockade (sedation), anticholinergic activity (delirium, falls), and a long half-life in the patient whose hepatic clearance is no longer young. The Beers Criteria flag it for exactly this reason. The patient who takes it three nights in a row may not be the same patient on day four.
Hold the contrast. Two drugs at the same primary receptor target. The one that crosses the wall sedates. The one that does not, does not.